These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890 [Abstract] [Full Text] [Related]
4. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype. Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB. J Huntingtons Dis; 2015 Aug; 4(1):17-36. PubMed ID: 26333255 [Abstract] [Full Text] [Related]
5. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, Thomas EA. Neurobiol Dis; 2011 Jun; 42(3):459-67. PubMed ID: 21334439 [Abstract] [Full Text] [Related]
6. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, André VM, Cepeda C, Watson JB, Levine MS. J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510 [Abstract] [Full Text] [Related]
7. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models. Flament J, Hantraye P, Valette J. Methods Mol Biol; 2018 Jan; 1780():285-301. PubMed ID: 29856025 [Abstract] [Full Text] [Related]
9. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group, Roos RA. Neurology; 2008 Nov 04; 71(19):1506-13. PubMed ID: 18981372 [Abstract] [Full Text] [Related]
10. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. J Neurochem; 2005 Oct 04; 95(2):553-62. PubMed ID: 16135087 [Abstract] [Full Text] [Related]
11. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, Jankowsky JL, Weiss A, Paylor R. Behav Brain Res; 2012 Apr 15; 229(2):308-19. PubMed ID: 22306231 [Abstract] [Full Text] [Related]
12. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease. Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. PLoS One; 2013 Apr 15; 8(12):e84726. PubMed ID: 24367693 [Abstract] [Full Text] [Related]
13. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset. Vatsavayai SC, Dallérac GM, Milnerwood AJ, Cummings DM, Rezaie P, Murphy KP, Hirst MC. Brain Res Bull; 2007 Apr 30; 72(2-3):98-102. PubMed ID: 17352932 [Abstract] [Full Text] [Related]
14. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. J Neurol Neurosurg Psychiatry; 2008 Feb 30; 79(2):130-5. PubMed ID: 17615168 [Abstract] [Full Text] [Related]
15. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP. Hum Mol Genet; 2001 Oct 01; 10(21):2425-35. PubMed ID: 11689489 [Abstract] [Full Text] [Related]
16. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Seo H, Kim W, Isacson O. Hum Mol Genet; 2008 Oct 15; 17(20):3144-53. PubMed ID: 18640989 [Abstract] [Full Text] [Related]
17. Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease. Skillings EA, Morton AJ. J Huntingtons Dis; 2016 Oct 15; 5(1):19-32. PubMed ID: 27031731 [Abstract] [Full Text] [Related]
18. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. Rué L, Bañez-Coronel M, Creus-Muncunill J, Giralt A, Alcalá-Vida R, Mentxaka G, Kagerbauer B, Zomeño-Abellán MT, Aranda Z, Venturi V, Pérez-Navarro E, Estivill X, Martí E. J Clin Invest; 2016 Nov 01; 126(11):4319-4330. PubMed ID: 27721240 [Abstract] [Full Text] [Related]
19. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M. Hum Mol Genet; 2018 Jun 15; 27(12):2125-2137. PubMed ID: 29668904 [Abstract] [Full Text] [Related]
20. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene. Panegyres PK, Goh JG. J Neurol Sci; 2011 Feb 15; 301(1-2):14-20. PubMed ID: 21147489 [Abstract] [Full Text] [Related] Page: [Next] [New Search]